こっちはもうすぐ終了するのかな？

Study Type :
Interventional (Clinical Trial)
Actual Enrollment :
580 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Actual Study Start Date :
November 12, 2015
Estimated Primary Completion Date :
October 31, 2018
Estimated Study Completion Date :
November 28, 2018

https://clinicaltrials.gov/ct2/show/study/NCT02597933?cond=nintedanib&;cntry=CN&rank=1